BEDMINSTER, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces new in vitro data showing the use of LNCs for the delivery of small oligonucleotides was presented yesterday in a poster session at TIDES USA 2024: Oligonucleotide & Peptide Therapeutics, a hybrid in-person and virtual conference underway in Boston. T ...

Matinas BioPharma Hldgs (NYSEMKT:MTNB) just reported results for the first quarter of 2024.Matinas BioPharma Hldgs reported earnings per share of -3 cents. This met the analyst estimate for EPS of -3 cents.The company did not report any revenue for the quarter.InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to a ...

Matinas BioPharma Holdings, Inc. (NYSE:MTNB) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Jody Cain - LHA Investor Relations Jerome Jabbour - Chief Executive Officer Theresa Matkovits - Chief Development Officer Terry Ferguson - Chief Medical Officer Keith Kucinski - Chief Financial Officer Conference Call Participants Scott Henry - Alliance Global Partners Operator Welcome, everyone, to the Matinas BioPharma First Quarter 2024 Financial Results Conference Call. Currently, al ...

Exhibit 99.1 Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update Recent $10 million financing expected to fund planned development programs and operations into the second quarter of 2025 Discussions to secure a partner to advance MAT2203 into the Phase 3 ORALTO trial remain on track Company’s strategy to expand its LNC platform into inflammation and oncology supported by favorable in vivo data in multiple disease models Conference call begins at 4:30 p.m. Eastern ti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38022 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware No. 46-3011414 (State or other juri ...

BEDMINSTER, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that James J. Ferguson, M.D., Chief Medical Officer of Matinas, will be presenting two abstracts at the ASGCT 27th Annual Meeting being held May 7-11, 2024 in Baltimore highlighting data from ex vivo, in vitro and in vivo studies evaluating the use of ...

BEDMINSTER, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that it will report first quarter 2024 financial results after market close on Thursday, May 9, 2024. Matinas management will host an investment community conference call and webcast to discuss financial results and provide a business update that day ...

BEDMINSTER, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that MAT2203, its oral formulation of the potent antifungal amphotericin B, demonstrated efficacy compared with placebo in treating the pulmonary mucormycosis fungal infections Rhizopus delemar and M. circinelloides f. jenssenii in immunosuppressed ...

Matinas BioPharma Holdings, Inc. (NYSE:MTNB) Q4 2023 Earnings Conference Call March 27, 2024 4:30 PM ET Company Participants Jody Cain - LHA Investor Relations Jerome Jabbour - Chief Executive Officer Theresa Matkovits - Chief Development Officer James Ferguson - Chief Medical Officer Keith Kucinski - Chief Financial Officer Conference Call Participants Rei Tan - BTIG Robert LeBoyer - Noble Capital Markets Operator Welcome, everyone, to the Matinas BioPharma 2023 Financial Results Conference Call. Currently ...

Exhibit 99.1 Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update Clear registration pathway and FDA agreement on the ORALTO Phase 3 trial for MAT2203 represent critical steps forward and supports partnership discussions Continued success of Compassionate/Expanded Use Access Program demonstrates potential of MAT2203 in treating multiple severe invasive fungal infections, including invasive aspergillosis Successful in vivo LNC platform studies demonstrating (a) the oral delivery of ...